Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

NCT ID: NCT04396119

Last Updated: 2020-09-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-11

Study Completion Date

2020-04-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors' understanding of cancer screening as a concept and the benefits of screening and early detection Explore survivors' level of awareness of and attitudes towards their lung cancer risk Explore survivors' views on the barriers and motivating factors that would impact their decision to attend a lung cancer screening test

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Details held in the ADAPT database at The Christie NHS Foundation trust
* Responded to most recent ADAPT study questionnaire (April - August 2019)
* Aged 18-80
* Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
* Able to provide informed consent
* Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or alkylating agent containing chemotherapy.

Exclusion Criteria

* Previous or current diagnosis of lung cancer
* Stated within 2019 health questionnaire that they did not wish to be contacted
* Have participated in lung cancer screening through the Manchester Lung Health Checks
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Christie NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Christie NHS Foundation Trust

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

276443

Identifier Type: OTHER

Identifier Source: secondary_id

CFTSp178

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Manchester Lung Health Study
NCT04409444 UNKNOWN
PD-L1 Expression in Lung Cancer
NCT04992715 UNKNOWN PHASE2
99mTc-H7ND SPECT/CT Imaging in NSCLC
NCT05999214 RECRUITING NA